The FDA has approved Amneal Pharmaceuticals’s generic version of Tobi tobramycin inhalation solution, the company said. The product is the New Jersey-based generic pharmaceutical company’s first inhalation solution.
Amneal co-CEO and Chairman Chirag Patel said, “Tobramycin is extremely exciting for us in that it’s a new dosage form for Amneal—proof we’re delivering the varied portfolio we committed to offering our customers.”
Read the Amneal press release.
